Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Sex differences of cerebrospinal fluid biomarkers in Alzheimer’s disease

View through CrossRef
AbstractBackgroundAlzheimer’s disease (AD) is more common in women than in men. Thus, to investigate the sex‐specific mechanism is important to understand the pathogenesis of AD. We examined the sex differences in levels of CSF biomarkers (tau, ptau‐181, Aβ42, HVA and 5HIAA) in AD.MethodThe subjects of this study consisted of clinically diagnosed 386 patients with AD (age 75.9±8.4 years, 237 women and 149 men). The clinical diagnosis was made based on the AD diagnostic criteria (NIA/AA, McKhann GM, et al., Alzheimers Dement 2011; 7: 263‐269). The CSF samples were obtained by lumbar puncture after informed consent was obtained. The levels of CSF tau, ptau‐181 and Aβ42 were measured by ELISA (Fujirebio, Belgium) according to the manufacturer’s protocol. The levels of CSF HVA and 5HIAA were measured by HPLC. We compared the levels of CSF biomarkers between women and men.ResultAge, the levels of CSF tau, ptau‐181 and Aβ42 showed no sex differences. The levels of CSF HVA (ng/ml) were 32.6±19.3 in women and 25.9±14.4 in men. The levels of 5HIAA were 19.1±11.7 in women and 14.8±7.7 in men. The levels of CSF HVA and 5HIAA were significantly higher in women than those in men (t‐test, HVA: p<0.001, 5HIAA: p<0.001).It has been reported that women have higher values of HVA and 5HIAA among normal subjects, due to higher monoamine oxidase (MAO) activity in women. The MAO‐A and MAO‐B genes are located on the X chromosome, and are controlled by XCI (X‐chromosome inactivation). However, the MAO genes may escape XCL MAO‐B has also been reported to be γ‐secretase associated protein and regulate neuronal amyloid β‐peptide levels. Thus, increased MAO‐B activity may be one of the reasons why AD is more common in women.ConclusionBoth CSF levels of HVA and 5HIAA were significantly higher in women in AD, presumably due to increased MAO activity.
Title: Sex differences of cerebrospinal fluid biomarkers in Alzheimer’s disease
Description:
AbstractBackgroundAlzheimer’s disease (AD) is more common in women than in men.
Thus, to investigate the sex‐specific mechanism is important to understand the pathogenesis of AD.
We examined the sex differences in levels of CSF biomarkers (tau, ptau‐181, Aβ42, HVA and 5HIAA) in AD.
MethodThe subjects of this study consisted of clinically diagnosed 386 patients with AD (age 75.
9±8.
4 years, 237 women and 149 men).
The clinical diagnosis was made based on the AD diagnostic criteria (NIA/AA, McKhann GM, et al.
, Alzheimers Dement 2011; 7: 263‐269).
The CSF samples were obtained by lumbar puncture after informed consent was obtained.
The levels of CSF tau, ptau‐181 and Aβ42 were measured by ELISA (Fujirebio, Belgium) according to the manufacturer’s protocol.
The levels of CSF HVA and 5HIAA were measured by HPLC.
We compared the levels of CSF biomarkers between women and men.
ResultAge, the levels of CSF tau, ptau‐181 and Aβ42 showed no sex differences.
The levels of CSF HVA (ng/ml) were 32.
6±19.
3 in women and 25.
9±14.
4 in men.
The levels of 5HIAA were 19.
1±11.
7 in women and 14.
8±7.
7 in men.
The levels of CSF HVA and 5HIAA were significantly higher in women than those in men (t‐test, HVA: p<0.
001, 5HIAA: p<0.
001).
It has been reported that women have higher values of HVA and 5HIAA among normal subjects, due to higher monoamine oxidase (MAO) activity in women.
The MAO‐A and MAO‐B genes are located on the X chromosome, and are controlled by XCI (X‐chromosome inactivation).
However, the MAO genes may escape XCL MAO‐B has also been reported to be γ‐secretase associated protein and regulate neuronal amyloid β‐peptide levels.
Thus, increased MAO‐B activity may be one of the reasons why AD is more common in women.
ConclusionBoth CSF levels of HVA and 5HIAA were significantly higher in women in AD, presumably due to increased MAO activity.

Related Results

ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration
ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration
AbstractUnder the ATN framework, cerebrospinal fluid analytes provide evidence of the presence or absence of Alzheimer’s disease pathological hallmarks: amyloid plaques (A), phosph...
Race, polygenic risk and their association with incident dementia among older US adults
Race, polygenic risk and their association with incident dementia among older US adults
AbstractDementia incidence increases steadily with age at rates that may vary across racial groups. This racial disparity may be attributable to polygenic risk, as well as lifestyl...
Penerapan Metode Convolutional Neural Network untuk Diagnosa Penyakit Alzheimer
Penerapan Metode Convolutional Neural Network untuk Diagnosa Penyakit Alzheimer
Abstract— Alzheimer's disease is a neurodegenerative disease that develops gradually, and is associated with cardiovascular and cerebrovascular problems. Alzheimer's is a serious d...
Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study
Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study
Abstract Early-onset Alzheimer’s disease constitutes ∼5–10% of Alzheimer’s disease. Its clinical characteristics and biomarker profiles are not well documented. To c...
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Abstract The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease and neurodegenerative effects is not fully understood. This study inves...
Use of biomarkers in the early detection of Alzheimer’s disease
Use of biomarkers in the early detection of Alzheimer’s disease
In 1906, Alois Alzheimer described the disease bearing his name, a progressive neurodegenerative pathology with high prevalence. This condition is characterized by progressive cogn...
Plasmalogen deficiency and the Alzheimer’s disease risk of apolipoprotein E4
Plasmalogen deficiency and the Alzheimer’s disease risk of apolipoprotein E4
Abstract The ε4 allele of the APOE gene, encoding the E4 isoform of apolipoprotein E, is the leading genetic risk factor for late-onset Alzheimer’s disease. While...
Sex differences in disease genetics
Sex differences in disease genetics
Abstract There is long-standing evidence for gene-by-sex interactions in disease risk, which can now be tested in genome-wide association studies with participant n...

Back to Top